Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;31(6):e2231.
doi: 10.1002/rmv.2231. Epub 2021 Mar 16.

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines

Daniele Focosi  1 , Fabrizio Maggi  2
Affiliations
Review

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines

Daniele Focosi et al. Rev Med Virol. 2021 Nov.

Abstract

The Spike protein is the target of both antibody-based therapeutics (convalescent plasma, polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect efficacy of those treatments. Hence, monitoring of mutations is necessary to forecast and readapt the inventory of therapeutics. Different phylogenetic nomenclatures have been used for the currently circulating SARS-CoV-2 clades. The Spike protein has different hotspots of mutation and deletion, the most dangerous for immune escape being the ones within the receptor binding domain (RBD), such as K417N/T, N439K, L452R, Y453F, S477N, E484K, and N501Y. Convergent evolution has led to different combinations of mutations among different clades. In this review we focus on the main variants of concern, that is, the so-called UK (B.1.1.7), South African (B.1.351) and Brazilian (P.1) strains.

Keywords: B.1.1.7; B.1.351; BNT162b2; COVID-19; LY-CoV555; LyCoV016; P.1; P.2; REGN10933; REGN10987; SARS-CoV-2; bamlanivimab; casirivimab; convalescent plasma; etesevimab; imdevimab; immune escape; mRNA-1273; mutations; neutralising antibody; polyclonal immunoglobulins.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

FIGURE 1
FIGURE 1
Linearised representation of Single nucleotide polymorphisms (SNPs) and deletions commonly detected in the S1 and S2 domains of the Spike protein, with a focus on the receptor binding domain (RBD) and receptor binding motif (RBM). Circle size represents relative abundance of the mutation in worldwide genome repositories as of January 2021. Mutations within RBD are represented on grey background
See this image and copyright information in PMC

References

    1. Convertino I, Tuccori M, Ferraro S, et al. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID‐19 patients. Crit Care. 2020;24:331. 10.1186/s13054-020-03020-3. - DOI - PMC - PubMed
    1. Tuccori M, Convertino I, Ferraro S, et al. The impact of the COVID‐19 “Infodemic” on drug‐utilization behaviors: implications for pharmacovigilance. Drug Saf. 2020;43:699–709. 10.1007/s40264-020-00965-w. - DOI - PMC - PubMed
    1. The RECOVERY Collaborative Group . Dexamethasone in hospitalized patients with Covid‐19—preliminary report. N Engl J Med. 2020;384:693–704. 10.1056/NEJMoa2021436. - DOI - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid‐19 ‐ final report. N Engl J Med. 2020;383:1813‐1826. 10.1056/NEJMoa2007764. - DOI - PMC - PubMed
    1. Yao H, Song Y, Chen Y, et al. Molecular architecture of the SARS‐CoV‐2 virus. Cell. 2020;183:730‐738. 10.1016/j.cell.2020.09.018.e713 - DOI - PMC - PubMed

MeSH terms